Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

The oral presentation will highlight safety and efficacy data from three cohorts of ARC-20, which evaluated casdatifan monotherapy in patients that had received both prior TKI and anti-PD-1 therapy.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of ...

“We are pleased to share the updated Phase 2 data through a late-breaking oral presentation at this year’s International Stroke Conference. These preliminary results show promising MRI-based ...

SHENZHEN, China, Oct. 15, 2024 /PRNewswire/ -- On October 15, 2024, the list of selected candidates for the oral report of the American Association for the Study of the Liver (AASLD 2024) annual ...

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison to placebo, treatment with REC-994 400 mg showed promi ...